Both genetic and pharmacological inhibition of METTL3 attenuated renal injury and inflammation, suggesting that the METTL3/TAB3 axis is a potential target for the treatment of AKI (Wang et al. 2022). This evidence concerns the gene METTL3 and acute kidney injury.